245 related articles for article (PubMed ID: 21501557)
1. Present status of nanoparticle research for treatment of tuberculosis.
Shegokar R; Al Shaal L; Mitri K
J Pharm Pharm Sci; 2011; 14(1):100-16. PubMed ID: 21501557
[TBL] [Abstract][Full Text] [Related]
2. Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy.
Beg S; Saini S; Imam SS; Rahman M; Swain S; Hasnain MS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):85-94. PubMed ID: 28480833
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis vaccines: hopes and hurdles.
Ahsan MJ; Garg SK; Vashistha B; Sharma P
Infect Disord Drug Targets; 2013 Oct; 13(5):318-21. PubMed ID: 24304353
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.
Grotz E; Tateosian N; Amiano N; Cagel M; Bernabeu E; Chiappetta DA; Moretton MA
Pharm Res; 2018 Sep; 35(11):213. PubMed ID: 30238168
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis: from molecular pathogenesis to effective drug carrier design.
Dube D; Agrawal GP; Vyas SP
Drug Discov Today; 2012 Jul; 17(13-14):760-73. PubMed ID: 22480870
[TBL] [Abstract][Full Text] [Related]
7. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
Banyal S; Malik P; Tuli HS; Mukherjee TK
Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
[TBL] [Abstract][Full Text] [Related]
8. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.
Gelperina S; Kisich K; Iseman MD; Heifets L
Am J Respir Crit Care Med; 2005 Dec; 172(12):1487-90. PubMed ID: 16151040
[TBL] [Abstract][Full Text] [Related]
9. Nano-carriers for the Treatment of Tuberculosis.
Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
[TBL] [Abstract][Full Text] [Related]
10. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
Sharma A; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
[TBL] [Abstract][Full Text] [Related]
12. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
13. Key targets and relevant inhibitors for the drug discovery of tuberculosis.
Xiong X; Xu Z; Yang Z; Liu Y; Wang D; Dong M; Parker EJ; Zhu W
Curr Drug Targets; 2013 Jun; 14(6):676-99. PubMed ID: 23547780
[TBL] [Abstract][Full Text] [Related]
14. Nano-based drug delivery optimization for tuberculosis treatment: A review.
Dahanayake MH; Jayasundera ACA
J Microbiol Methods; 2021 Feb; 181():106127. PubMed ID: 33359155
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
[TBL] [Abstract][Full Text] [Related]
16. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey R; Khuller GK
Indian J Exp Biol; 2006 May; 44(5):357-66. PubMed ID: 16708887
[TBL] [Abstract][Full Text] [Related]
18. Fighting tuberculosis: old drugs, new formulations.
Blasi P; Schoubben A; Giovagnoli S; Rossi C; Ricci M
Expert Opin Drug Deliv; 2009 Sep; 6(9):977-93. PubMed ID: 19678791
[TBL] [Abstract][Full Text] [Related]
19. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
Ullah Z; Athar MT; Samad A
Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
